AstraZeneca Results Presentation Deck
AstraZeneca in Lung Cancer
Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030
Est. epi (G7)
IO sensitive
c.70%
EGFRm
c.16%
Other tumour
drivers c.12%
HER2m
c.2%
established SoC
resectable
Stg. I-III
~200K
Imfinzi
AEGEAN
volrustomig + CTx
NEOCOAST-2
Tagrisso
ADAURA
Tagrisso
neoADAURA
unresectable
Stg. 1-11
~30K
Imfinzi
w/SBRT
PACIFIC-4
Stg. III
~70K
CRT → Imfinzi
PACIFIC
CRT + Imfinzi
PACIFIC-2
Imfinzi combos
PACIFIC-8, -9
improvements across
PD-L1 spectrum
CRT → Tagrisso
LAURA
CRT Imfinzi
PACIFIC
1L
~350K
Imfinzi + Imjudo + CTx
POSEIDON
Dato-DXd + 10
TROPION-Lung08/TROPION-Lung07/AVANZAR
Enhertu + 10 + CTX
DESTINY-Lung03
volrustomig + CTx
eVOLVE-Lung02
rilvegostomig (PD1/TIGIT)
ARTEMIDE-1
Tagrisso
FLAURA
Tagrisso + CTx
FLAURA2
metastatic
Enhertu
DESTINY-Lung04
2L+
~290K
Imfinzi + ceralasertib
LATIFY
Dato-DXd
TROPION-Lung01
AZD9592 (EGFR/CMET ADC)
EGRET
sabestomig
(PD1/TIM3)
savolitinib + Tagrisso
SAFFRON/SAVANNAH
AZD9592 (EGFR/CMET ADC)
EGRET
Dato-DXd
TROPION-Lung01
TROPION-Lung05
APPENDIX | Oncology tumour maps
Enhertu
DESTINY-Lung02
Leading the future of
lung cancer treatment
Establishing Tagrisso as backbone
TKI in EGFRm
Imfinzi leading 10 in unresectable
Advancing best-in-class ADCs to
replace systemic chemotherapy
Delivering next-wave bispecifics
to improve on PD1/PD-L1
Developing novel combinations,
including 10 + ADCs
Investing behind new
technologies and platforms,
including cell therapy and
testing/screening
Est epi (G7) = estimated epidemiology across G7 (US, EU5, JP); Stg. = stage; CTx = chemotherapy; SBRT = stereotactic body radiation therapy; CRT = chemoradiotherapy; pembro = pembrolizumab; 10 = immunotherapy; ADC =
antibody-drug conjugate; PD1 = programmed cell death protein 1; EGFR = epidermal growth factor receptor; c-MET = mesenchymal-epithelial transition factor; TIGIT = T-cell immunoreceptor with immunoglobulin and ITIM domains;
35 CTLA4 = cytotoxic T-lymphocyte associated protein 4; TIM3 = T-cell immunoglobulin and mucin domain-containing protein 3; SoC = standard of care; TKI = tyrosine kinase inhibitor; HER2m = human epidermal growth factor receptor
2 mutated. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Compugen (rilvegostomig).
BView entire presentation